Immune escape of γ-herpesviruses from adaptive immunity

Reviews in Medical Virology

Volumn 24, Issue 6, 2014, Pages 365-378

  Hu, Zhuting ^a   Usherwood, Edward J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOMODULATING AGENT; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURFACE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; EPSTEIN BARR VIRUS; GAMMAHERPESVIRINAE; GENE INDUCTION; HERPES VIRUS INFECTION; HOST CELL; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE EVASION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RNA DEGRADATION; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS IMMUNITY; ANIMAL; GENETICS; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNE EVASION;

EID: 84926197178     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1791     Document Type: Review

References (153)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702-703.
2. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
3. Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27(Suppl 2): S31-42. DOI: 10.1038/onc.2009.351
4. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310: 207-211.
5. Tarbouriech N, Buisson M, Geoui T, Daenke S, Cusack S, Burmeister WP. Structural genomics of the Epstein-Barr virus. Acta Crystallographica Section D: Biological Crystallography 2006; 62: 1276-1285. DOI: 10.1107/S0907444906030034
6. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. New England Journal of Medicine 2004; 350: 1328-1337. DOI: 10.1056/NEJMra032015
7. Renne R, Lagunoff M, Zhong W, Ganem D. The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. Journal of Virology 1996; 70: 8151-8154.
8. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 14862-14867.
9. Coscoy L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nature Reviews Immunology 2007; 7: 391-401. DOI: 10.1038/nri2076
10. Ablashi DV, Chatlynne LG, Whitman JE Jr., Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clinical Microbiology Reviews 2002; 15: 439-464.
11. Chatlynne LG, Ablashi DV. Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Seminars in Cancer Biology 1999; 9: 175-185. DOI: 10.1006/scbi.1998.0089
12. Blaskovic D, Stancekova M, Svobodova J, Mistrikova J. Isolation of five strains of herpesviruses from two species of free living small rodents. Acta Virologica 1980; 24: 468.
13. Blasdell K, McCracken C, Morris A, et al. The wood mouse is a natural host for Murid herpesvirus 4. Journal of General Virology 2003; 84: 111-113.
14. Efstathiou S, Ho YM, Hall S, Styles CJ, Scott SD, Gompels UA. Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri. Journal of General Virology 1990; 71: 1365-1372.
15. Virgin HWt, Latreille P, Wamsley P, et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. Journal of Virology 1997; 71: 5894-5904.
16. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA. Virological and pathological features of mice infected with murine gammaherpesvirus 68. Journal of General Virology 1992; 73: 2347-2356.
17. Sunil-Chandra NP, Efstathiou S, Nash AA. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. Journal of General Virology 1992; 73: 3275-3279.
18. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. Journal of Immunology 2000; 165: 1074-1081.
19. Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. Journal of Experimental Medicine 1998; 187: 1941-1951.
20. Doherty PC, Christensen JP, Belz GT, Stevenson PG, Sangster MY. Dissecting the host response to a γ-herpesvirus. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 2001; 356: 581-593. DOI: 10.1098/rstb.2000.0786
21. Nash AA, Dutia BM, Stewart JP, Davison AJ. Natural history of murine γ-herpesvirus infection. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 2001; 356: 569-579. DOI: 10.1098/rstb.2000.0779
22. + T cells. Journal of Experimental Medicine 2000; 192: 943-952.
23. Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL. Control of murine gammaherpesvirus infection is independent of NK cells. European Journal of Immunology 2005; 35: 2956-2961. DOI: 10.1002/eji.200526245
24. Usherwood EJ, Ward KA, Blackman MA, Stewart JP, Woodland DL. Latent antigen vaccination in a model gammaherpesvirus infection. Journal of Virology 2001; 75: 8283-8288.
25. Tsai CY, Hu Z, Zhang W, Usherwood EJ. Strain-dependent requirement for IFN-γ for respiratory control and immunotherapy in murine gammaherpesvirus infection. Viral Immunology 2011; 24: 273-280. DOI: 10.1089/vim.2011.0004
26. Tsai CY, Allie SR, Zhang W, Usherwood EJ. MicroRNA miR-155 affects antiviral effector and effector memory CD8 T cell differentiation. Journal of Virology 2013; 87: 2348-2351. DOI: 10.1128/JVI.01742-12
27. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annual Review of Immunology 2011; 29: 351-397. DOI: 10.1146/annurev-immunol-072710-081639
28. Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ. Viral evasion of T cell immunity: ancient mechanisms offering new applications. Current Opinion in Immunology 2011; 23: 96-103. DOI: 10.1016/j.coi.2010.11.005
29. Speck SH, Ganem D. Viral latency and its regulation: lessons from the γ-herpesviruses. Cell Host & Microbe 2010; 8: 100-115. DOI: 10.1016/j.chom.2010.06.014
30. Areste C, Blackbourn DJ. Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends in Microbiology 2009; 17: 119-129. DOI: 10.1016/j.tim.2008.12.001
31. Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nature Reviews Immunology 2009; 9: 503-513. DOI: 10.1038/nri2575
32. Liang C, Lee JS, Jung JU. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Seminars in Cancer Biology 2008; 18: 423-436. DOI: 10.1016/j.semcancer.2008.09.003
33. Li J, Qian CN, Zeng YX. Regulatory T cells and EBV associated malignancies. International Immunopharmacology 2009; 9: 590-592. DOI: 10.1016/j.intimp.2009.01.015
34. Elliott T, Williams A. The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex. Immunological Reviews 2005; 207: 89-99. DOI: 10.1111/j.0105-2896.2005.00311.x
35. Baresova P, Pitha PM, Lubyova B. Distinct roles of Kaposi's sarcoma-associated herpesvirus-encoded vIRFs in inflammatory response and cancer. Journal of Virology 2013; 87: 9398-9410. DOI: 10.1128/JVI.03315-12
36. Lagos D, Trotter MW, Vart RJ, et al. Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood 2007; 109: 1550-1558. DOI: 10.1182/blood-2006-05-024034
37. Glaunsinger B, Ganem D. Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Molecular Cell 2004; 13: 713-723.
38. Lee YJ, Glaunsinger BA. Aberrant herpesvirus-induced polyadenylation correlates with cellular messenger RNA destruction. PLoS Biology 2009; 7: e1000107. DOI: 10.1371/journal.pbio.1000107
39. Kumar GR, Glaunsinger BA. Nuclear import of cytoplasmic poly(A) binding protein restricts gene expression via hyperadenylation and nuclear retention of mRNA. Molecular and Cellular Biology 2010; 30: 4996-5008. DOI: 10.1128/MCB.00600-10
40. Rowe M, Glaunsinger B, van Leeuwen D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 3366-3371. DOI: 10.1073/pnas.0611128104
41. Buisson M, Geoui T, Flot D, et al. A bridge crosses the active-site canyon of the Epstein-Barr virus nuclease with DNase and RNase activities. Journal of Molecular Biology 2009; 391: 717-728. DOI: 10.1016/j.jmb.2009.06.034
42. Bagneris C, Briggs LC, Savva R, Ebrahimi B, Barrett TE. Crystal structure of a KSHV-SOX-DNA complex: insights into the molecular mechanisms underlying DNase activity and host shutoff. Nucleic Acids Research 2011; 39: 5744-5756. DOI: 10.1093/nar/gkr111
43. + T cells through an additional host shutoff function. Journal of Virology 2008; 82: 2385-2393. DOI: 10.1128/JVI.01946-07
44. Covarrubias S, Richner JM, Clyde K, Lee YJ, Glaunsinger BA. Host shutoff is a conserved phenotype of gammaherpesvirus infection and is orchestrated exclusively from the cytoplasm. Journal of Virology 2009; 83: 9554-9566. DOI: 10.1128/JVI.01051-09
45. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annual Review of Immunology 1999; 17: 739-779. DOI: 10.1146/annurev.immunol.17.1.739
46. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
47. + T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 3318-3323. DOI: 10.1073/pnas.0813320106
48. + T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005; 106: 3166-3174. DOI: 10.1182/blood-2005-01-0432
49. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688. DOI: 10.1038/375685a0
50. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 12616-12621.
51. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003; 301: 1371-1374. DOI: 10.1126/science.1088902
52. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999; 284: 641-644.
53. Lan K, Kuppers DA, Verma SC, Robertson ES. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. Journal of Virology 2004; 78: 6585-6594. DOI: 10.1128/JVI.78.12.6585-6594.2004
54. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. Journal of Virology 2007; 81: 8225-8235. DOI: 10.1128/JVI.00411-07
55. Fowler P, Marques S, Simas JP, Efstathiou S. ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. Journal of General Virology 2003; 84: 3405-3416.
56. Bennett NJ, May JS, Stevenson PG. Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biology 2005; 3: e120. DOI: 10.1371/journal.pbio.0030120
57. Boname JM, Stevenson PG. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 2001; 15: 627-636.
58. Boname JM, de Lima BD, Lehner PJ, Stevenson PG. Viral degradation of the MHC class I peptide loading complex. Immunity 2004; 20: 305-317.
59. Stevenson PG, Efstathiou S, Doherty PC, Lehner PJ. Inhibition of MHC class I-restricted antigen presentation by γ2-herpesviruses. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 8455-8460. DOI: 10.1073/pnas.150240097
60. Lybarger L, Wang X, Harris MR, Virgin HWt, Hansen TH. Virus subversion of the MHC class I peptide-loading complex. Immunity 2003; 18: 121-130.
61. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. Journal of Experimental Medicine 2007; 204: 1863-1873. DOI: 10.1084/jem.20070256
62. Horst D, Favaloro V, Vilardi F, et al. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. Journal of Immunology 2011; 186: 3594-3605. DOI: 10.4049/jimmunol.1002656
63. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. Journal of Virology 2005; 79: 536-546. DOI: 10.1128/JVI.79.1.536-546.2005
64. Zuo J, Currin A, Griffin BD, et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathogens 2009; 5: e1000255. DOI: 10.1371/journal.ppat.1000255
65. Griffin BD, Gram AM, Mulder A, et al. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. Journal of Immunology 2013; 190: 1672-1684. DOI: 10.4049/jimmunol.1102462
66. Lehner PJ, Hoer S, Dodd R, Duncan LM. Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases. Immunological Reviews 2005; 207: 112-125. DOI: 10.1111/j.0105-2896.2005.00314.x
67. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 8051-8056. DOI: 10.1073/pnas.140129797
68. Coscoy L, Sanchez DJ, Ganem D. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. Journal of Cell Biology 2001; 155: 1265-1273. DOI: 10.1083/jcb.200111010
69. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. Journal of Virology 2000; 74: 5300-5309.
70. + T cells in immunity to viruses. Nature Reviews Immunology 2012; 12: 136-148. DOI: 10.1038/nri3152
71. Pieters J. MHC class II compartments: specialized organelles of the endocytic pathway in antigen presenting cells. Biological Chemistry 1997; 378: 751-758.
72. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007; 26: 79-92. DOI: 10.1016/j.immuni.2006.10.018
73. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109(Suppl): S21-33.
74. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO Journal 1997; 16: 2851-2860. DOI: 10.1093/emboj/16.10.2851
75. Morris AC, Beresford GW, Mooney MR, Boss JM. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Molecular and Cellular Biology 2002; 22: 4781-4791.
76. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arteriosclerosis, Thrombosis, and Vascular Biology 2011; 31: 980-985. DOI: 10.1161/ATVBAHA.110.207464
77. Butler LM, Jeffery HC, Wheat RL, et al. Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3. Journal of Virology 2012; 86: 7158-7166. DOI: 10.1128/JVI.06908-11
78. Wies E, Mori Y, Hahn A, et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008; 111: 320-327. DOI: 10.1182/blood-2007-05-092288
79. Schmidt K, Wies E, Neipel F. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. Journal of Virology 2011; 85: 4530-4537. DOI: 10.1128/JVI.02123-10
80. Bi X, Yang L, Mancl ME, Barnes BJ. Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction. Journal of Interferon and Cytokine Research 2011; 31: 373-382. DOI: 10.1089/jir.2010.0084
81. Wies E, Hahn AS, Schmidt K, et al. The Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. Journal of Biological Chemistry 2009; 284: 8525-8538. DOI: 10.1074/jbc.M809252200
82. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Advances in Cancer Research 2007; 97: 81-109. DOI: 10.1016/S0065-230X(06)97004-3
83. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC. Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001; 15: 787-799.
84. Li D, Qian L, Chen C, et al. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Journal of Immunology 2009; 182: 1799-1809. DOI: 10.4049/jimmunol.0802686
85. + T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathogens 2011; 7: e1002455. DOI: 10.1371/journal.ppat.1002455
86. Li Q, Turk SM, Hutt-Fletcher LM. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. Journal of Virology 1995; 69: 3987-3994.
87. Li Q, Spriggs MK, Kovats S, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. Journal of Virology 1997; 71: 4657-4662.
88. Ressing ME, van Leeuwen D, Verreck FA, et al. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 11583-11588. DOI: 10.1073/pnas.2034960100
89. Ressing ME, van Leeuwen D, Verreck FA, et al. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. Journal of Virology 2005; 79: 841-852. DOI: 10.1128/JVI.79.2.841-852.2005
90. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. Journal of Experimental Medicine 2000; 191: 1649-1660.
91. Paludan C, Schmid D, Landthaler M, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005; 307: 593-596. DOI: 10.1126/science.1104904
92. Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 2165-2170. DOI: 10.1073/pnas.0909448107
93. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252. DOI: 10.1038/32588
94. Li L, Liu D, Hutt-Fletcher L, Morgan A, Masucci MG, Levitsky V. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002; 99: 3725-3734.
95. Stebbing J, Gazzard B, Portsmouth S, et al. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood 2003; 102: 1806-1814. DOI: 10.1182/blood-2003-03-0891
96. Cirone M, Lucania G, Aleandri S, et al. Suppression of dendritic cell differentiation through cytokines released by primary effusion lymphoma cells. Immunology Letters 2008; 120: 37-41. DOI: 10.1016/j.imlet.2008.06.011
97. Cirone M, Lucania G, Bergamo P, Trivedi P, Frati L, Faggioni A. Human herpesvirus 8 (HHV-8) inhibits monocyte differentiation into dendritic cells and impairs their immunostimulatory activity. Immunology Letters 2007; 113: 40-46. DOI: 10.1016/j.imlet.2007.07.013
98. Cirone M, Conte V, Farina A, et al. HHV-8 reduces dendritic cell migration through down-regulation of cell-surface CCR6 and CCR7 and cytoskeleton reorganization. Virology Journal 2012; 9: 92. DOI: 10.1186/1743-422X-9-92
99. Rappocciolo G, Jenkins FJ, Hensler HR, et al. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. Journal of Immunology 2006; 176: 1741-1749.
100. Bertram EM, Dawicki W, Watts TH. Role of T cell costimulation in anti-viral immunity. Seminars in Immunology 2004; 16: 185-196. DOI: 10.1016/j.smim.2004.02.006
101. + T-cell function and immune surveillance of murine gammaherpesvirus 68. Journal of Virology 2006; 80: 9159-9170. DOI: 10.1128/JVI.00422-06
102. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619-624. DOI: 10.1038/341619a0
103. Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. Journal of Clinical Investigation 2001; 107: 1599-1606. DOI: 10.1172/JCI12432
104. Ishido S, Choi JK, Lee BS, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000; 13: 365-374.
105. Thomas M, Boname JM, Field S, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 1656-1661. DOI: 10.1073/pnas.0707883105
106. Hochreiter R, Ptaschinski C, Kunkel SL, Rochford R. Murine gammaherpesvirus-68 productively infects immature dendritic cells and blocks maturation. Journal of General Virology 2007; 88: 1896-1905. DOI: 10.1099/vir.0.82931-0
107. Wan YY. Regulatory T cells: immune suppression and beyond. Cellular and molecular immunology 2010; 7: 204-210. DOI: 10.1038/cmi.2010.20
108. + T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645. DOI: 10.1016/j.immuni.2009.04.010
109. high regulatory T cells in nasopharyngeal carcinoma patients. British Journal of Cancer 2007; 96: 617-622. DOI: 10.1038/sj.bjc.6603580
110. + type-1 regulatory T cells. American Journal of Transplantation 2007; 7: 1215-1223. DOI: 10.1111/j.1600-6143.2007.01740.x
111. Takegawa S, Jin Z, Nakayama T, et al. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Science 2008; 99: 296-302. DOI: 10.1111/j.1349-7006.2007.00687.x
112. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. American Journal of Pathology 2008; 173: 195-204. DOI: 10.2353/ajpath.2008.070845
113. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Research 2005; 65: 1577-1586. DOI: 10.1158/0008-5472.CAN-04-2552
114. + regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil. Medical Oncology 2012; 29: 3614-3619. DOI: 10.1007/s12032-012-0299-4
115. + T cells. Journal of Immunology 2005; 175: 7093-7097.
116. + T cells. Journal of Immunology 2007; 178: 3265-3271.
117. + T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. Journal of Immunology 2013; 191: 312-322. DOI: 10.4049/jimmunol.1201773
118. + T cells arise in the absence of CD4 help and compromise control of persistent virus. Journal of Immunology 2011; 186: 6218-6226. DOI: 10.4049/jimmunol.1003812
119. + T regulatory cell activity following infection. Journal of Immunology 2006; 177: 4670-4678.
120. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. Journal of Immunology 2008; 180: 5771-5777.
121. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nature Medicine 2009; 15: 277-284. DOI: 10.1038/nm.1929
122. Brockman MA, Kwon DS, Tighe DP, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009; 114: 346-356. DOI: 10.1182/blood-2008-12-191296
123. Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. Journal of Pathology 2000; 190: 143-149. DOI: 10.1002/(SICI)1096-9896(200002)190:2<143::AID-PATH519>3.0.CO;2-5
124. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992; 80: 1289-1298.
125. Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. Journal of Experimental Medicine 1993; 177: 295-304.
126. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999; 94: 2871-2879.
127. Peacock JW, Bost KL. Murine gammaherpesvirus-68-induced interleukin-10 increases viral burden, but limits virus-induced splenomegaly and leukocytosis. Immunology 2001; 104: 109-117. DOI: imm1286 [pii]
128. Flano E, Kayhan B, Woodland DL, Blackman MA. Infection of dendritic cells by a γ2-herpesvirus induces functional modulation. Journal of Immunology 2005; 175: 3225-3234.
129. Slobedman B, Barry PA, Spencer JV, Avdic S, Abendroth A. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. Journal of Virology 2009; 83: 9618-9629. DOI: 10.1128/JVI.01098-09
130. Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Seminars in Cancer Biology 2008; 18: 388-396. DOI: 10.1016/j.semcancer.2008.10.004
131. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. Journal of Immunology 2003; 170: 6183-6189.
132. Incrocci R, McCormack M, Swanson-Mungerson M. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas. Journal of General Virology 2013; 94: 1127-1133. DOI: 10.1099/vir.0.049221-0
133. Mahot S, Sergeant A, Drouet E, Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. Journal of General Virology 2003; 84: 965-974.
134. Iwakiri D, Takada K. Role of EBERs in the pathogenesis of EBV infection. Advances in Cancer Research 2010; 107: 119-136. DOI: 10.1016/S0065-230X(10)07004-1
135. - RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO Journal 2000; 19: 6742-6750. DOI: 10.1093/emboj/19.24.6742
136. Zhu Y, Haecker I, Yang Y, Gao SJ, Renne R. γ-Herpesvirus-encoded miRNAs and their roles in viral biology and pathogenesis. Current Opinion in Virology 2013; 3: 266-275. DOI: 10.1016/j.coviro.2013.05.013
137. Gottwein E. Kaposi's sarcoma-associated herpesvirus microRNAs. Frontiers in Microbiology 2012; 3: 165. DOI: 10.3389/fmicb.2012.00165
138. Bai Z, Huang Y, Li W, et al. Genomewide mapping and screening of Kaposi's sarcoma-associated herpesvirus (KSHV) 3' untranslated regions identify bicistronic and polycistronic viral transcripts as frequent targets of KSHV microRNAs. Journal of Virology 2014; 88: 377-392. DOI: 10.1128/JVI.02689-13
139. Qin Z, Kearney P, Plaisance K, Parsons CH. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. Journal of Leukocyte Biology 2010; 87: 25-34.
140. Herskowitz JH, Jacoby MA, Speck SH. The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells. Journal of Virology 2005; 79: 2261-2273. DOI: 10.1128/JVI.79.4.2261-2273.2005
141. de Oliveira VL, Almeida SC, Soares HR, Parkhouse RM. Selective B-cell expression of the MHV-68 latency-associated M2 protein regulates T-dependent antibody response and inhibits apoptosis upon viral infection. Journal of General Virology 2013; 94: 1613-1623. DOI: 10.1099/vir.0.050013-0
142. Liang X, Shin YC, Means RE, Jung JU. Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein. Journal of Virology 2004; 78: 12416-12427. DOI: 10.1128/JVI.78.22.12416-12427.2004
143. Siegel AM, Herskowitz JH, Speck SH. The MHV68 M2 protein drives IL-10 dependent B cell proliferation and differentiation. PLoS Pathogens 2008; 4: e1000039. DOI: 10.1371/journal.ppat.1000039
144. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248: 1230-1234.
145. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. Journal of Experimental Medicine 2000; 191: 213-224.
146. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathogens 2012; 8: e1002704. DOI: 10.1371/journal.ppat.1002704
147. Zeidler R, Eissner G, Meissner P, et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997; 90: 2390-2397.
148. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830-832.
149. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. Journal of Experimental Medicine 1991; 174: 915-924.
150. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 1890-1893.
151. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. Journal of Immunology 1990; 145: 4167-4173.
152. Vieira P, de Waal-Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 1172-1176.
153. Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. Journal of Experimental Medicine 1990; 172: 1625-1631.